PT - JOURNAL ARTICLE AU - Oliveira, Eduardo AU - Parikh, Amay AU - Lopez-Ruiz, Arnaldo AU - Carrilo, Maria AU - Goldberg, Joshua AU - Cearras, Martin AU - Fernainy, Khaled AU - Andersen, Sonja AU - Mercado, Luis AU - Guan, Jian AU - Zafar, Hammad AU - Louzon, Patricia AU - Carr, Amy AU - Baloch, Natasha AU - Pratley, Richard AU - Silverstry, Scott AU - Hsu, Vincent AU - Sniffen, Jason AU - Herrera, Victor AU - Finkler, Neil TI - ICU Outcomes and Survival in Patients with Severe COVID-19 in the Largest Health Care System in Central Florida AID - 10.1101/2020.08.25.20181909 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.25.20181909 4099 - http://medrxiv.org/content/early/2020/08/31/2020.08.25.20181909.short 4100 - http://medrxiv.org/content/early/2020/08/31/2020.08.25.20181909.full AB - Background Observational studies have consistently described poor clinical outcomes and increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who require mechanical ventilation (MV). Our study describes the clinical characteristics and outcomes of patients with severe COVID-19 admitted to ICU in the largest health care system in the state of Florida, United States.Methods Retrospective cohort study of patients admitted to ICU due to severe COVID-19 in AdventHealth health system in Orlando, Florida from March 11th until May 18th, 2020. Patients were characterized based on demographics, baseline comorbidities, severity of illness, medical management including experimental therapies, laboratory markers and ventilator parameters. Major clinical outcomes analyzed at the end of the study period were: hospital and ICU length of stay, MV-related mortality and overall hospital mortality of ICU patients.Results Out of total of 1283 patients with COVID-19, 131 (10.2%) met criteria for ICU admission (median age: 61 years [interquartile range {IQR}, 49.5-71.5]; 35.1% female). Common comorbidities were hypertension (84; 64.1%), and diabetes (54; 41.2%). Of the 131 ICU patients, 109 (83.2%) required MV and 9 (6.9%) received ECMO. Lower positive end expiratory pressure (PEEP) were observed in survivors [9.2 (7.7-10.4)] vs non-survivors [10 (9.1-12.9] p= 0.004]. Compared to non-survivors, survivors had a longer MV length of stay (LOS) [14 (IQR 8-22) vs 8.5 (IQR 5-10.8) p< 0.001], Hospital LOS [21 (IQR 13-31) vs 10 (7-1) p< 0.001] and ICU LOS [14 (IQR 7-24) vs 9.5 (IQR 6-11), p < 0.001]. The overall hospital mortality and MV-related mortality were 19.8% and 23.8% respectively. After exclusion of hospitalized patients, the hospital and MV-related mortality rates were 21.6% and 26.5% respectively.Conclusions Our study demonstrates an important improvement in mortality of patients with severe COVID-19 who required ICU admission and MV in comparison to previous observational reports and emphasize the importance of standard of care measures in the management of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Expenses related to this publication are divided equally between the authors who are members of the division of critical care, infectious diseases and research institute at AdventHealth.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB Approval and Consent to participate: This protocol and end points for this observational retrospective study was evaluated and approved by the Institutional review board (IRB) of AdventHealth Central Florida Division. The research proposal, population involved and objectives of the study were also evaluated and approved by the Ethical committee of AdventHealth. Upon admission to hospital and/or ICU, patients or their family members agreed and signed appropriate consent to authorize physicians of the division of critical care as well as other consulting subspecialists to enroll them in different randomized trial for experimental therapies as wells as in observational/retrospective studies. Consent for publication: Patients and family members have agreed and signed appropriate consent to authorize AdventHealth Research Institute to access and utilize unidentified demographic and clinical information data saved in the electronic medical record and related only to the hospital admission due to COVID-19 for the purpose of clinical research, medical publications and/or medical education. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailability of supporting data: Unidentified and analyzed numerical data of all the variables and clinical outcomes that are reported in this article can be provided to the editorial board and statistics specialist of the journal upon request.